IL108528A - Use of erythropoietin to prepare a pharmaceutical composition suitable for giving through the cheers - Google Patents

Use of erythropoietin to prepare a pharmaceutical composition suitable for giving through the cheers

Info

Publication number: IL108528A
Authority: IL; Israel
Prior art keywords: epo; erythropoietin; composition; nebulizer; use according
Prior art date: 1993-02-04

Application number

IL10852894A

Other languages

English (en)

Hebrew (he)

Other versions

IL108528A0 (en

Original Assignee

Amgen Inc Thousand Oaks

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-04

Filing date

1994-02-02

Publication date

1999-05-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21760356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL108528(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-02-02 Application filed by Amgen Inc Thousand Oaks filed Critical Amgen Inc Thousand Oaks

1994-05-30 Publication of IL108528A0 publication Critical patent/IL108528A0/xx

1999-05-09 Publication of IL108528A publication Critical patent/IL108528A/en

Links

102000003951 Erythropoietin Human genes 0.000 title claims abstract description 123
108090000394 Erythropoietin Proteins 0.000 title claims abstract description 123
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 123
229940105423 erythropoietin Drugs 0.000 title claims abstract description 121
230000002685 pulmonary effect Effects 0.000 title claims abstract description 38
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
239000000443 aerosol Substances 0.000 claims abstract description 49
238000002360 preparation method Methods 0.000 claims abstract description 10
239000000203 mixture Substances 0.000 claims description 72
239000002245 particle Substances 0.000 claims description 25
239000000843 powder Substances 0.000 claims description 21
239000006199 nebulizer Substances 0.000 claims description 17
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 15
102000044890 human EPO Human genes 0.000 claims description 15
229940071648 metered dose inhaler Drugs 0.000 claims description 7
108020004414 DNA Proteins 0.000 claims description 6
102000053602 DNA Human genes 0.000 claims description 5
238000010521 absorption reaction Methods 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 4
239000003380 propellant Substances 0.000 claims description 4
241000699802 Cricetulus griseus Species 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
210000001672 ovary Anatomy 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
230000002708 enhancing effect Effects 0.000 claims description 2
101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims 8
239000007900 aqueous suspension Substances 0.000 claims 2
210000003743 erythrocyte Anatomy 0.000 abstract description 33
208000007502 anemia Diseases 0.000 abstract description 18
230000010437 erythropoiesis Effects 0.000 abstract description 6
238000009472 formulation Methods 0.000 description 52
210000004072 lung Anatomy 0.000 description 26
210000004369 blood Anatomy 0.000 description 24
239000008280 blood Substances 0.000 description 24
238000005534 hematocrit Methods 0.000 description 22
108090000623 proteins and genes Proteins 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 19
241000700159 Rattus Species 0.000 description 18
238000012384 transportation and delivery Methods 0.000 description 18
210000004027 cell Anatomy 0.000 description 17
241001465754 Metazoa Species 0.000 description 13
239000000243 solution Substances 0.000 description 13
230000000694 effects Effects 0.000 description 11
239000003814 drug Substances 0.000 description 10
238000000034 method Methods 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
241000124008 Mammalia Species 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
239000004094 surface-active agent Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
239000000126 substance Substances 0.000 description 7
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
229930195725 Mannitol Natural products 0.000 description 6
150000001413 amino acids Chemical group 0.000 description 6
238000000151 deposition Methods 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
239000000594 mannitol Substances 0.000 description 6
235000010355 mannitol Nutrition 0.000 description 6
238000003127 radioimmunoassay Methods 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000282412 Homo Species 0.000 description 5
210000002821 alveolar epithelial cell Anatomy 0.000 description 5
230000008021 deposition Effects 0.000 description 5
-1 polyoxyethylene Polymers 0.000 description 5
238000011282 treatment Methods 0.000 description 5
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
108091006905 Human Serum Albumin Proteins 0.000 description 4
102000008100 Human Serum Albumin Human genes 0.000 description 4
108010071390 Serum Albumin Proteins 0.000 description 4
102000007562 Serum Albumin Human genes 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
210000001601 blood-air barrier Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
238000009826 distribution Methods 0.000 description 4
239000000284 extract Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
230000000241 respiratory effect Effects 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
238000010254 subcutaneous injection Methods 0.000 description 4
239000007929 subcutaneous injection Substances 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
206010065973 Iron Overload Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000002033 PVDF binder Substances 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
238000012387 aerosolization Methods 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
238000004166 bioassay Methods 0.000 description 3
238000004820 blood count Methods 0.000 description 3
210000003123 bronchiole Anatomy 0.000 description 3
239000004067 bulking agent Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
208000020832 chronic kidney disease Diseases 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
208000028208 end stage renal disease Diseases 0.000 description 3
201000000523 end stage renal failure Diseases 0.000 description 3
210000003989 endothelium vascular Anatomy 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
210000000777 hematopoietic system Anatomy 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229920002981 polyvinylidene fluoride Polymers 0.000 description 3
238000011160 research Methods 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
102400000686 Endothelin-1 Human genes 0.000 description 2
101800004490 Endothelin-1 Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
108010000817 Leuprolide Proteins 0.000 description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
241001494479 Pecora Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
241000473945 Theria <moth genus> Species 0.000 description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000007792 addition Methods 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
210000003484 anatomy Anatomy 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000012754 cardiac puncture Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000001886 ciliary effect Effects 0.000 description 2
230000004087 circulation Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
230000000994 depressogenic effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
235000013305 food Nutrition 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
229960004338 leuprorelin Drugs 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000009145 protein modification Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
230000001839 systemic circulation Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000000287 tissue oxygenation Effects 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
IZUAHLHTQJCCLJ-UHFFFAOYSA-N (2-chloro-1,1,2,2-tetrafluoroethyl) hypochlorite Chemical compound FC(F)(Cl)C(F)(F)OCl IZUAHLHTQJCCLJ-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
101710081722 Antitrypsin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241000700198 Cavia Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000027205 Congenital disease Diseases 0.000 description 1
208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
102100020880 Kit ligand Human genes 0.000 description 1
101710177504 Kit ligand Proteins 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
229940082819 Luteinizing hormone releasing hormone (LHRH) agonist Drugs 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
230000003435 bronchoconstrictive effect Effects 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
210000000215 ciliated epithelial cell Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000000913 erythropoietic effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000005286 illumination Methods 0.000 description 1
230000003116 impacting effect Effects 0.000 description 1
238000012623 in vivo measurement Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
231100000037 inhalation toxicity test Toxicity 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
238000003801 milling Methods 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
231100000043 nose-only exposure Toxicity 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000002482 oligosaccharides Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
230000000581 polycythemic effect Effects 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920000131 polyvinylidene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
210000003456 pulmonary alveoli Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
239000000837 restrainer Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005070 sampling Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000021309 simple sugar Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001578 tight junction Anatomy 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
229940070384 ventolin Drugs 0.000 description 1
230000007279 water homeostasis Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL10852894A 1993-02-04 1994-02-02 Use of erythropoietin to prepare a pharmaceutical composition suitable for giving through the cheers IL108528A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/013,514 US5354934A (en)	1993-02-04	1993-02-04	Pulmonary administration of erythropoietin

Publications (2)

Publication Number	Publication Date
IL108528A0 IL108528A0 (en)	1994-05-30
IL108528A true IL108528A (en)	1999-05-09

Family

ID=21760356

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10852894A IL108528A (en)	1993-02-04	1994-02-02	Use of erythropoietin to prepare a pharmaceutical composition suitable for giving through the cheers

Country Status (13)

Country	Link
US (1)	US5354934A (fr)
EP (1)	EP0613683B2 (fr)
JP (1)	JP4338214B2 (fr)
AT (1)	ATE187061T1 (fr)
AU (1)	AU677378B2 (fr)
CA (1)	CA2155334C (fr)
DE (1)	DE69421835T3 (fr)
DK (1)	DK0613683T4 (fr)
ES (1)	ES2139678T5 (fr)
GR (1)	GR3032374T3 (fr)
IL (1)	IL108528A (fr)
WO (1)	WO1994017784A1 (fr)
ZA (1)	ZA94737B (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2032831T5 (es)	1986-08-19	2001-02-16	Genentech Inc	Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
US6582728B1 (en)	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US5661125A (en) *	1992-08-06	1997-08-26	Amgen, Inc.	Stable and preserved erythropoietin compositions
CZ286632B6 (cs)	1992-09-29	2000-05-17	Inhale Therapeutic Systems	Farmaceutický prostředek
US7448375B2 (en)	1993-01-29	2008-11-11	Aradigm Corporation	Method of treating diabetes mellitus in a patient
US6012450A (en) *	1993-01-29	2000-01-11	Aradigm Corporation	Intrapulmonary delivery of hematopoietic drug
US6024090A (en)	1993-01-29	2000-02-15	Aradigm Corporation	Method of treating a diabetic patient by aerosolized administration of insulin lispro
EP1462096B1 (fr)	1994-03-07	2008-12-10	Nektar Therapeutics	Methodes et compositions pour la délivrance pulmonale d'insulin
US6051256A (en) *	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
CN1073119C (zh)	1994-05-18	2001-10-17	吸入治疗系统公司	干扰素干粉配方的方法及组合物
US6586006B2 (en)	1994-08-04	2003-07-01	Elan Drug Delivery Limited	Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
IL116085A (en) *	1994-12-16	1999-12-31	Ortho Pharma Corp	Spray dried erythropoietin
US6485726B1 (en)	1995-01-17	2002-11-26	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of therapeutics
WO1996030068A1 (fr)	1995-03-31	1996-10-03	Aradigm Corporation	Administration intrapulmonaire d'un medicament hematopoietique
ES2237767T3 (es) *	1995-04-14	2005-08-01	Nektar Therapeutics	Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US5869451A (en)	1995-06-07	1999-02-09	Glaxo Group Limited	Peptides and compounds that bind to a receptor
ATE390439T1 (de)	1995-06-07	2008-04-15	Glaxo Group Ltd	An einem thrombopoietin rezeptor bindende peptide und zusammensetzungen
DE19539574A1 (de) *	1995-10-25	1997-04-30	Boehringer Mannheim Gmbh	Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5875776A (en) *	1996-04-09	1999-03-02	Vivorx Pharmaceuticals, Inc.	Dry powder inhaler
HUP9901575A3 (en) *	1996-04-29	1999-11-29	Dura Pharmaceuticals Inc San D	Methods of dry powder inhalation
US7091311B2 (en)	1996-06-07	2006-08-15	Smithkline Beecham Corporation	Peptides and compounds that bind to a receptor
GB9612297D0 (en) *	1996-06-11	1996-08-14	Minnesota Mining & Mfg	Medicinal aerosol formulations
US5952226A (en) *	1996-11-05	1999-09-14	Modex Therapeutiques	Hypoxia responsive EPO producing cells
US20030203036A1 (en)	2000-03-17	2003-10-30	Gordon Marc S.	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) *	1997-02-21	1997-04-09	Bradford Particle Design Ltd	Method and apparatus for the formation of particles
DE19733651A1 (de) *	1997-08-04	1999-02-18	Boehringer Ingelheim Pharma	Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
US6309623B1 (en)	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en)	1997-09-29	2005-09-20	Nektar Therapeutics	Stabilized preparations for use in nebulizers
CA2304975C (fr) †	1997-09-29	2009-06-16	Inhale Therapeutic Systems, Inc.	Preparations stabilisees pour aerosols-doseurs
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US6696411B1 (en)	1998-04-22	2004-02-24	Cornell Research Foundation, Inc.	Canine erythropoietin gene and recombinant protein
WO1999054486A1 (fr) *	1998-04-22	1999-10-28	Cornell Research Foundation, Inc.	Gene de l'erithropoietine canine et proteine recombinee
RU2128517C1 (ru) *	1998-07-20	1999-04-10	Колобков Сергей Леонидович	Стабилизированный водный раствор эритропоэтина
CN1367701A (zh) *	1999-05-11	2002-09-04	奥索－麦克尼尔药物公司	红细胞生成素给药的药代动力学和药效模型
US7332275B2 (en)	1999-10-13	2008-02-19	Sequenom, Inc.	Methods for detecting methylated nucleotides
KR20020056923A (ko)	1999-11-18	2002-07-10	코르바스 인터내셔날, 인코포레이티드	엔도텔리아제를 암호화하는 핵산, 엔도텔리아제 및 이의용도
EP1244432A2 (fr) *	1999-12-30	2002-10-02	Chiron Corporation	Procedes d'administration pulmonaire d'interleukine-2
US7700341B2 (en)	2000-02-03	2010-04-20	Dendreon Corporation	Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DK1280520T4 (en)	2000-05-10	2018-06-25	Novartis Ag	Phospholipid based powders for drug delivery
DK1311285T4 (en) *	2000-05-15	2017-07-24	Hoffmann La Roche	Liquid pharmaceutical composition containing an erythropoietin derivative
US7575761B2 (en)	2000-06-30	2009-08-18	Novartis Pharma Ag	Spray drying process control of drying kinetics
GB0027357D0 (en) *	2000-11-09	2000-12-27	Bradford Particle Design Plc	Particle formation methods and their products
ATE420630T1 (de) *	2000-11-29	2009-01-15	Itoham Foods Inc	Pulverzubereitungen und verfahren zu ihrer herstellung
US7767643B2 (en)	2000-12-29	2010-08-03	The Kenneth S. Warren Institute, Inc.	Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) *	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1471871B1 (fr)	2001-02-02	2007-05-02	Ortho-McNeil Pharmaceutical, Inc.	Traitement de dysfonctionnements neurologiques au moyen de sulfamates de fructopyranose et d'erythropoietine
US20030072717A1 (en) *	2001-02-23	2003-04-17	Vapotronics, Inc.	Inhalation device having an optimized air flow path
WO2002072786A2 (fr)	2001-03-13	2002-09-19	Corvas International, Inc.	Molecules d'acides nucleiques codant pour une serine protease transmembranaire 7, polypeptides codes et procedes associes
GB0107106D0 (en) *	2001-03-21	2001-05-09	Boehringer Ingelheim Pharma	Powder inhaler formulations
JP2004535166A (ja)	2001-03-22	2004-11-25	デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー	セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
WO2002077267A2 (fr)	2001-03-27	2002-10-03	Dendreon San Diego Llc	Molecules d'acide nucleique codant une serine protease transmembranaire 9, polypeptides codes et procedes fondes sur ces derniers
WO2002092841A2 (fr)	2001-05-14	2002-11-21	Dendreon San Diego Llc	Molecules d'acides nucleiques codant pour une serine protease transmembranaire 10, polypeptides codes et methodes associees
WO2002094342A2 (fr) *	2001-05-21	2002-11-28	Vapotronics, Inc.	Compositions pour l'administration de proteines par la voie pulmonaire
EG24184A (en) *	2001-06-15	2008-10-08	Otsuka Pharma Co Ltd	Dry powder inhalation system for transpulmonary
GB0208742D0 (en)	2002-04-17	2002-05-29	Bradford Particle Design Ltd	Particulate materials
WO2003053411A1 (fr)	2001-12-19	2003-07-03	Nektar Therapeutics	Administration pulmonaire d'aminoglycosides
WO2003055526A2 (fr) *	2001-12-21	2003-07-10	Maxygen Aps	Conjugues d'erythropoietine
US7582284B2 (en)	2002-04-17	2009-09-01	Nektar Therapeutics	Particulate materials
GB0216562D0 (en)	2002-04-25	2002-08-28	Bradford Particle Design Ltd	Particulate materials
WO2003093296A2 (fr)	2002-05-03	2003-11-13	Sequenom, Inc.	Muteines de proteines d'ancrage de kinase, leurs peptides, et procedes associes
US9339459B2 (en)	2003-04-24	2016-05-17	Nektar Therapeutics	Particulate materials
US20040009908A1 (en) *	2002-07-10	2004-01-15	Stamler Jonathan S.	Methods for treating or preventing ischemic injury
DE10234165B4 (de) *	2002-07-26	2008-01-03	Advanced Micro Devices, Inc., Sunnyvale	Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
DE10234192B4 (de)	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
MXPA05003057A (es)	2002-09-18	2006-04-18	Johnson & Johnson	Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
EP1852441B1 (fr)	2002-09-24	2012-03-28	The Burnham Institute	Agents qui modulent l'activité du récepteur EPH
CA2547531C (fr) *	2002-11-26	2013-11-12	Seacoast Neuroscience, Inc.	Articles polymeres flottants pour l'administration d'agents therapeutiques au systeme nerveux central
US20040132645A1 (en) *	2003-01-03	2004-07-08	Knox Susan J.	Methods for modulating effects of radiation in a subject
EP1596854A4 (fr)	2003-02-14	2007-06-06	Childrens Hosp & Res Ct Oak	Traitement d'etats pathologiques associes a la biodisponibilite reduite de l'oxyde nitrique, y compris des etats pathologiques causes par l'activite elevee de l'arginase
WO2004091495A2 (fr) *	2003-04-09	2004-10-28	University Of Utah Research Foundation	Compositions et procedes associes a la production d'erythropoietine
DE102004004509B4 (de) *	2004-01-23	2010-07-01	Epoplus Gmbh Co.Kg	Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
EP1848461A2 (fr) *	2005-02-16	2007-10-31	Nektar Therapeutics Al, Corporation	Conjugues d'une fraction d'epo et d'un polymere
US7927787B2 (en)	2006-06-28	2011-04-19	The Invention Science Fund I, Llc	Methods and systems for analysis of nutraceutical associated components
US10296720B2 (en)	2005-11-30	2019-05-21	Gearbox Llc	Computational systems and methods related to nutraceuticals
US8297028B2 (en)	2006-06-14	2012-10-30	The Invention Science Fund I, Llc	Individualized pharmaceutical selection and packaging
US7974856B2 (en)	2005-11-30	2011-07-05	The Invention Science Fund I, Llc	Computational systems and methods related to nutraceuticals
US20080210748A1 (en)	2005-11-30	2008-09-04	Searete Llc, A Limited Liability Corporation Of The State Of Delaware,	Systems and methods for receiving pathogen related information and responding
US8000981B2 (en)	2005-11-30	2011-08-16	The Invention Science Fund I, Llc	Methods and systems related to receiving nutraceutical associated information
US8340944B2 (en)	2005-11-30	2012-12-25	The Invention Science Fund I, Llc	Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7827042B2 (en)	2005-11-30	2010-11-02	The Invention Science Fund I, Inc	Methods and systems related to transmission of nutraceutical associated information
TW200810773A (en) *	2006-04-19	2008-03-01	Alba Therapeutics Corp	Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents
ATE530644T1 (de)	2006-07-05	2011-11-15	Catalyst Biosciences Inc	Protease-screening-verfahren und dadurch identifizierte proteasen
ES2538082T3 (es)	2007-02-11	2015-06-17	Map Pharmaceuticals Inc	Método de administración terapéutica de DHE para permitir el rápido alivio de migraña mientras que se minimiza el perfil de efectos secundarios
TWI626945B (zh)	2008-08-14	2018-06-21	艾瑟勒朗法瑪公司	使用ｇｄｆ阱以增加紅血球水平
US9808030B2 (en)	2011-02-11	2017-11-07	Grain Processing Corporation	Salt composition
EP3875104B1 (fr) *	2011-10-17	2025-01-22	Acceleron Pharma Inc.	Méthodes et compositions destinées au traitement d'une érythropoïèse inefficace
KR101855242B1 (ko)	2012-01-26	2018-05-09	크리스토퍼 제이. 소레스	펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
US20140350087A9 (en)	2012-03-22	2014-11-27	Halozyme, Inc.	Oncovector Nucleic Acid Molecules and Methods of Use
US10105410B2 (en)	2014-03-10	2018-10-23	Rambam Med-Tech Ltd.	Heparanase inhibitory peptides and use thereof for treating clinical pathologies
US20180050005A1 (en)	2016-08-16	2018-02-22	Janssen Pharmaceutica Nv	Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
EP4316595A3 (fr)	2016-09-02	2024-04-17	Christopher J. Soares	Utilisation d'antagonistes du récepteur cgrp pour le traitement du glaucome
KR102688415B1 (ko)	2017-07-26	2024-07-24	잔센파마슈티카엔.브이.	표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 조성물
MX2021008942A (es)	2019-01-25	2021-08-24	Janssen Pharmaceutica Nv	Metodos para mitigar efectos toxicos vesicantes y gas caustico.
MX2021008943A (es)	2019-01-25	2021-11-04	Janssen Pharmaceutica Nv	Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.
WO2020154637A1 (fr)	2019-01-25	2020-07-30	Janssen Pharmaceutica Nv	Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques
WO2020201038A1 (fr)	2019-03-29	2020-10-08	Pieris Pharmaceuticals Gmbh	Administration inhalée de mutéines de lipocaline
BR112022001185A2 (pt)	2019-08-01	2022-03-15	Acm Biolabs Pte Ltd	Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
US20230256082A1 (en)	2020-04-24	2023-08-17	Acm Biolabs Pte Ltd	Vaccine against human-pathogenic coronaviruses
CA3193643A1 (fr)	2020-12-11	2022-06-16	Madhavan Nallani	Modulation de la reponse immunitaire th1/th2 par administration de deux populations de polymersomes presentant un antigene associe et un adjuvant associe
EP4288033B1 (fr)	2021-02-02	2025-06-25	ACM Biolabs Pte Ltd	Polymérosome associé à un adjuvant pour utilisation dans la stimulation d'une réponse immunitaire
JP2024515564A (ja)	2021-04-08	2024-04-10	ピエリスファーマシューティカルズゲーエムベーハー	結合組織増殖因子（ｃｔｇｆ）に特異的な新規リポカリンムテイン
CA3234340A1 (fr)	2021-10-01	2023-04-06	Janssen Pharmaceutica N.V.	Procedes d'augmentation de la production de cellules progenitrices
WO2023168426A1 (fr)	2022-03-03	2023-09-07	Enosi Therapeutics Corporation	Compositions et cellules contenant des mélanges de protéines de fusion oligo-trap (ofps) et leurs utilisations
WO2024186690A2 (fr)	2023-03-03	2024-09-12	Enosi Therapeutics Corporation	Protéines de fusion oligo-pièges (ofp) et leurs utilisations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1575050A1 (de)	1966-01-12	1972-04-13	Misto Gen Equipment Co	Ultraschall-Nebelerzeugungsgeraet
JPS59163313A (ja) †	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
US4703008A (en) *	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
US4635627A (en) *	1984-09-13	1987-01-13	Riker Laboratories, Inc.	Apparatus and method
GB2177914B (en) *	1985-06-04	1989-10-25	Chugai Pharmaceutical Co Ltd	A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
ES2032831T5 (es) †	1986-08-19	2001-02-16	Genentech Inc	Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
US5013718A (en) *	1986-11-21	1991-05-07	Amgen, Inc.	Method for treating iron overload using EPO
JP2656944B2 (ja) †	1987-04-30	1997-09-24	クーパーラボラトリーズ	タンパク質性治療剤のエアロゾール化
JP2851627B2 (ja) *	1987-10-15	1999-01-27	シンテックス（ユー・エス・エイ）インコーポレイテッド	粉末形態ポリプペチド類の経鼻投与
US5011678A (en) *	1989-02-01	1991-04-30	California Biotechnology Inc.	Composition and method for administration of pharmaceutically active substances
JPH05963A (ja) *	1990-04-13	1993-01-08	Toray Ind Inc	ポリペプチド類組成物
US5394866A (en)	1991-03-05	1995-03-07	Aradigm Corporation	Automatic aerosol medication delivery system and methods
JP3507486B2 (ja) *	1991-03-15	2004-03-15	アムジエン・インコーポレーテツド	顆粒球コロニー刺激因子の肺内投与
GB9116610D0 (en) †	1991-08-01	1991-09-18	Danbiosyst Uk	Preparation of microparticles
JPH07503154A (ja) †	1992-01-21	1995-04-06	エス・アール・アイ・インターナシヨナル	微細化ポリペプチド薬剤の改良調製方法
US5626871A (en) †	1992-06-12	1997-05-06	Teijin Limited	Preparation for intratracheobronchial administration

1993
- 1993-02-04 US US08/013,514 patent/US5354934A/en not_active Expired - Lifetime
1994
- 1994-01-28 AU AU60987/94A patent/AU677378B2/en not_active Expired
- 1994-01-28 JP JP51812594A patent/JP4338214B2/ja not_active Expired - Lifetime
- 1994-01-28 WO PCT/US1994/001070 patent/WO1994017784A1/fr not_active Ceased
- 1994-01-28 CA CA002155334A patent/CA2155334C/fr not_active Expired - Lifetime
- 1994-02-02 DK DK94101461T patent/DK0613683T4/da active
- 1994-02-02 DE DE69421835T patent/DE69421835T3/de not_active Expired - Lifetime
- 1994-02-02 IL IL10852894A patent/IL108528A/en not_active IP Right Cessation
- 1994-02-02 EP EP94101461A patent/EP0613683B2/fr not_active Expired - Lifetime
- 1994-02-02 ES ES94101461T patent/ES2139678T5/es not_active Expired - Lifetime
- 1994-02-02 AT AT94101461T patent/ATE187061T1/de active
- 1994-02-03 ZA ZA94737A patent/ZA94737B/xx unknown
2000
- 2000-01-14 GR GR20000400073T patent/GR3032374T3/el unknown

Also Published As

Publication number	Publication date
DK0613683T3 (da)	2000-04-03
DK0613683T4 (da)	2003-07-14
US5354934A (en)	1994-10-11
DE69421835T3 (de)	2003-12-24
ES2139678T3 (es)	2000-02-16
DE69421835T2 (de)	2000-05-18
HK1009239A1 (en)	1999-05-28
EP0613683B2 (fr)	2003-06-04
IL108528A0 (en)	1994-05-30
ES2139678T5 (es)	2003-12-01
EP0613683A1 (fr)	1994-09-07
GR3032374T3 (en)	2000-04-27
ZA94737B (en)	1994-09-29
ATE187061T1 (de)	1999-12-15
CA2155334C (fr)	2006-08-15
AU677378B2 (en)	1997-04-24
WO1994017784A1 (fr)	1994-08-18
AU6098794A (en)	1994-08-29
JPH08507753A (ja)	1996-08-20
DE69421835D1 (de)	2000-01-05
CA2155334A1 (fr)	1994-08-18
EP0613683B1 (fr)	1999-12-01
JP4338214B2 (ja)	2009-10-07

Legal Events

Date	Code	Title
1999-09-22	FF	Patent granted
2000-07-26	KB	Patent renewed
2000-08-31	KB	Patent renewed
2004-03-28	KB	Patent renewed
2008-02-10	KB	Patent renewed
2012-02-29	KB	Patent renewed
2014-09-30	EXP	Patent expired

Publication	Publication Date	Title
EP0613683B1 (fr)	1999-12-01	Utilisation d'érythropoiètine pour la préparation d'une composition pharmaceutique pour l'administration pulmonaire ou inhalation
EP0505123B1 (fr)	1997-01-08	Administration par voie pulmonaire de G-CSF
US6565841B1 (en)	2003-05-20	Pulmonary administration of granulocyte colony stimulating factor
US7456150B1 (en)	2008-11-25	Pulmonary delivery of active fragments of parathyroid hormone
KR100620338B1 (ko)	2006-09-13	에어로졸형 활성 제제 전달 방법
US6436902B1 (en)	2002-08-20	Therapeutic preparations for inhalation
JP2003519175A (ja)	2003-06-17	インターロイキン−２の肺送達のための方法
US20090123422A1 (en)	2009-05-14	Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-y
US20050008580A1 (en)	2005-01-13	Hemophilia treatment by inhalation of coagulation factors
JP2007524607A6 (ja)	2007-12-06	凝固因子の吸入による血友病処置
HK1009239B (en)	2000-07-07	Use of erythropoietin for the preparation of a pharmaceutical composition for pulmonary administration or inhalation
KR20220154214A (ko)	2022-11-21	흡입용 gm-csf의 액상 제제